A Biotech Power Move? ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
 |
| A message from Interactive Offers | 
NanoViricides (NYSE: NNVC) may be the most critical company to have on your radar as concerns about measles escalate!
The measles outbreak has been capturing many headlines in recent weeks. Hundreds of cases have broken out in the U.S. and most recently someone who was diagnosed traveled through several places in D.C. while contagious, including an Amtrak train, officials said.
There is no treatment available for measles; the lack of treatment is fueling the spread of this highly contagious disease. What if there was an answer to combatting measles as well as other deadly diseases such as Covid, bird flu, and RSV?
This highlights a revolutionary antiviral drug called NV-387 from emerging tiny biotech firm NanoViricides, Inc. (NYSE: NNVC), a Phase II-ready biopharmaceutical company developing antiviral drug treatments.
NV-387 mimics host-side signature required by viruses that does not change even as the viruses keep changing. In particular, NV-387 mimics heparan-sulfate-like structures to which over 90% of human pathogenic viruses are known to bind. NV-387 is a polymeric nanomachine that "looks like" a cell to the virus, and the virus ends up being engulfed by the shape-shifting NV-387 polymeric micelles, and thereby the virus is blocked from infecting cells in the first place.
NNVC has recently suggested that its revolutionary broad-spectrum antiviral drug NV-387 could have strong potential for the treatment of measles!
NV-387 was found to cure a lethal RSV infection in an animal model. Both Measles virus and RSV belong to the same family of viruses called paramyxoviruses. This family of viruses use heparan sulfated proteoglycans as their first stop, congregating next to cells, before gaining entry into cells.
According to NNVC, only a treatment for measles can effectively limit transmission of the virus and spread of the contagion. It is illogical and unscientific to believe that vaccination, which is being widely promoted, would have any immediate effect for controlling the current outbreak. This is because the vaccinated person will only become protected several weeks after receiving the vaccine dose. Additionally, immune-compromised subjects cannot be vaccinated.
While hundreds of millions of dollars of taxpayer money have gone towards ineffective antiviral drugs, NNVC is poised to cause a revolution with its drug-candidate that has the potential to treat many viral diseases including measles!
Learn how drug candidate NV-387 may be the very best weapon to fight viruses and shield the world from future pandemics!
This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7,000 for multiple Dedicated Email Sends, Newsletter Sponsorship, and SMS sends between April 10, 2025 and April 16, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
| | |
| |
ليست هناك تعليقات:
إرسال تعليق